Astley-Sparke Philip 4

What Happened Philip Astley‑Sparke, a director of enGene Therapeutics, was granted an award of 31,000 derivative shares (reported as a derivative acquisition) on June 16, 2026. The filing shows a reported acquisition price of $0.00 for the award; this reflects the grant itself, not an immediate cash purchase or sale.

Key Details

• Transaction date: 2026-06-16 (Form 4 filed 2026-06-17)
• Transaction type/code: A — Grant/award (derivative)
• Shares/units granted: 31,000 (reported at $0.00)
• Shares owned after transaction: not specified in the Form 4
• Vesting note: The option vests in full on the earlier of (i) the first anniversary of the vesting commencement date (vesting commencement date was June 9, 2026) or (ii) the registrant’s 2027 annual meeting of shareholders (footnote F1)
• Timeliness: Filing appears timely (filed next calendar day)

Context This transaction is a derivative award (option/award grant) rather than an open‑market purchase or sale. The $0.00 reported is the grant reporting amount and does not indicate an exercise price or immediate cash outlay; vesting must occur before any exercise/right to shares is realized. Such grants are common for board compensation; they do not by themselves indicate intent to buy or sell stock.